Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2012-04-20 | Mr. Richard brings to the Board extensive business development experience, having led that function at three separate life science companies and played a primary role in establishing numerous pharmaceutical alliances. In addition, the breadth of Mr. Richard’s current roles enables him to view issues that we face from a variety of perspectives, including as an executive, investor, director and transaction professional. |
| 2013-04-17 | Mr. Richard brings to the Board extensive business development experience, having led that function at three separate life science companies and played a primary role in establishing numerous pharmaceutical alliances. In addition, the breadth of Mr. Richard’s current roles enables him to view issues that we face from a variety of perspectives, including as an executive, investor, director and business development professional. |
| 2014-04-18 | Mr. Richard is an operating partner at the life science investment firm Phase4 Partners... Mr. Richard brings to the Board extensive business development experience, having led that function at three separate life science companies and played a primary role in establishing numerous pharmaceutical alliances. |
| 2015-11-23 | John P. Richard, director, no software-related skills indicated. |
| 2016-04-25 | Mr. Richard brings to the Board extensive business development experience, having led that function at three separate life science companies and played a primary role in establishing numerous pharmaceutical alliances. |
| 2017-01-12 | John P. Richard |
| 2017-05-18 | Mr. Richard is the co-founder and head of corporate development at Mereo BioPharma Group plc., and has served as a non-executive director for the life science investment firm Phase4 Partners. |
| 2018-05-11 | Mr. Richard brings to the Board extensive business development experience, having led that function at three separate life science companies and played a primary role in establishing numerous pharmaceutical alliances. |
| 2019-05-02 | Mr. Richard is co-founder and head of corporate development at Mereo BioPharma Group plc and has served as a senior business advisor to biotechnology companies. |
| Filing Date | Source Excerpt |
|---|---|
| 2013-10-01 | John P. Richard, age 56, has served as a member of our Board of Directors since August 2013. ... Mr. Richard’s extensive executive, venture capital and business development experience, having led that function at several life science companies and establishing numerous pharmaceutical alliances, led to the conclusion that he should serve on the Company’s Board of Directors. ... Nominating and Corporate Governance Committee Member. ... Director Compensation Table does not list compensation for Mr. Richard. |
| 2014-10-03 | John P. Richard, age 57, has served as a member of the Company’s Board of Directors since August 2013. Mr. Richard is currently an Operating Partner and non-executive director of Phase4 Partners, a venture capital firm based in London, UK. |
| 2015-09-30 | The members of the Company’s Audit Committee are Ms. VanLent (Chair), Mr. Dougherty and Mr. Richard. |
| 2016-09-27 | John P. Richard, age 59, has served as a member of the Company’s Board of Directors since August 2013. ... Mr. Richard’s extensive executive, strategic, financial and business development experience within the biotechnology industry, and having led the business development function at several companies resulting in numerous pharmaceutical alliances, led to the conclusion that he should serve on the Company’s Board of Directors. |
| 2018-02-26 | John P. Richard has served as a member of the board of directors since 2013. For fiscal 2018, he serves on the Audit and Compensation Committees. Director Compensation 2017: $60,815. |
| 2019-03-11 | John P. Richard has served as a member of our board of directors since 2013. Mr. Richard is co-founder and Head of Corporate Development for Mereo BioPharma Group plc, a London-based biopharmaceutical company started in 2015. |
Data sourced from SEC filings. Last updated: 2026-02-03